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Microorganisms, particularly bacteria, are frequently found in the lower airways of COPD
patients, both in stable state and during exacerbations. The hostepathogen relationship in
COPD is a complex, dynamic process characterised by frequent changes in pathogens, their
strains and loads, and subsequent host immune responses.
Exacerbations are detrimental events in the course of COPD and evidence suggests that 70%
may be caused by microorganisms. When considering bacterial exacerbations, recent findings
based on molecular typing have demonstrated that the acquisition of new strains of bacteria or
antigenic changes in pre-existing strains are the most important triggers for exacerbation
onset.
Even in clinically stable COPD patients the presence of microorganisms in their lower airways
may cause harmful effects and induce chronic low-grade airway inflammation leading to
increased exacerbation frequency, an accelerated decline in lung function and impaired
health-related quality of life. Besides intraluminal localisation in the distal airways, bacteria
can be found in the bronchial walls and parenchymal lung tissue of COPD patients. Therefore,
the isolation of pathogenic bacteria in stable COPD should be considered as a form of chronic
infection rather than colonisation. This new approach may have important implications for the
management of patients with COPD.
ª 2012 Elsevier Ltd. All rights reserved.neumologia, Hospital Clı´nic, Villarroel 170, 08036 Barcelona, Spain.
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The role of microorganisms, especially bacteria, in the
pathogenesis of chronic obstructive pulmonary disease
(COPD) has been the focus of interest for several decades,
although many questions remain to be answered. While in
the 1950s and 1960s microorganisms were considered
among the main aetiologic factors in COPD, and in the 1970s
and 1980s their role was minimised, interest in this subject
has rekindled in recent years with the introduction of new
research techniques which have provided interesting and
rather surprising discoveries. The difficulties and limita-
tions of the microbiological assessment of different respi-
ratory samples, the unclear significance of isolation of the
same pathogens during both stable COPD and exacerbations
and the absence of a standardised definition of COPD
exacerbation are only some of the “problems” faced when
investigating this issue and will be addressed in depth in
this review. Another topic that will be discussed in detail is
the significance of the presence of microorganisms,
particularly bacterial, in the distal airways during stable
COPD, which has recently become of increasing interest
due to the emerging evidence that microorganisms may
have an active role in the evolution of the disease.
Isolation of bacteria from respiratory
specimens during stable COPD
Microorganisms are one of the main aetiologic factors
involved in exacerbations of COPD.1e13 In contrast, under-
standing of their role during stable phases of the disease is
still incomplete, although some studies have suggested that
they actively contribute to chronic airway inflammation
leading to the progression of COPD.13e19
Our knowledge of the bacterial species that can be
found in the lower airways in stable COPD is based on
qualitative and quantitative cultures of spontaneous or
induced sputum samples, bronchoscopic protected spec-
imen brush (PSB), as well as bronchial lavage (BL) and
bronchoalveolar lavage (BAL) samples.16e20 Novel, non-
culture detection methods have recently been introduced
in respiratory research, although broader use remains
limited by their cost. These nonculture-based techniques
include polymerase chain reaction (PCR) for the detectionof microbial nucleic acid in respiratory specimens,21,22
molecular typing based on polyacrylamide and pulsed-
field gel electrophoresis to distinguish different bacterial
strains,3,22,23 in situ hybridisation and immunofluorescence
microscopy for detection of intracellular microorganisms in
bronchial biopsy specimens.24 Although sputum samples are
easier to collect, these samples are mainly obtained from
the large airways which are often contaminated by upper
airway microbial flora, thereby reducing the reliability of
the culture. In addition, PCR studies to detect bacterial
nucleic acid have demonstrated false negatives with
sputum cultures.21,22 In contrast, contamination by upper
airway flora is avoided with the use of PSB, BL and BAL
culture samples, but the use of fiberoptic bronchoscopy has
inherent risks and cost. Additionally, bronchoscopic
methods are unsuitable when repeated sampling is
required, such as in longitudinal studies.
Another point that should be taken into consideration
regarding colonisation is the cut-off value to define a posi-
tive culture, which, in most cases, is arbitrary. The
thresholds for positive cultures used in most of the recently
published studies are as follows: 102 or 105 colony-
forming units/millilitre (CFU/ml) for sputum,14,17,18,25
102 CFU/ml for BL,26 and 102 or 103 CFU/ml for PSB
and BAL samples.2,16,19,27e33
Bacterial species isolated from respiratory specimens
are usually divided into two groups: potentially pathogenic
microorganisms (PPMs) and non-potentially pathogenic
microorganisms (non-PPMs).16,28,34 PPMs are recognised as
agents causing respiratory infections and include Haemo-
philus spp. (nontypeable Haemophilus influenzae (NTHi),
Haemophilus parainfluenzae and Haemophilus haemolyti-
cus), Streptococcus pneumoniae, Moraxella catarrhalis,
Staphylococcus aureus, Pseudomonas aeruginosa and some
members of a large Enterobacteriaceae family (Escherichia
coli, Proteus mirabilis, Klebsiella pneumoniae, Serratia
marcescens, Enterobacter cloacae).16,28,34 Non-PPMs are
usually not involved in respiratory infections in immuno-
competent individuals; they belong to the normal oropha-
ryngeal or gastrointestinal flora and include bacteria such
as Corynebacterium spp., Neisseria spp., Enterococcus
spp., coagulase-negative Staphylococcus spp. and Strepto-
coccus viridans group and fungi such as Candida
spp.28,32The distribution of bacterial species into PPMs and
non-PPMs may change over time in accordance with the
12 Z. Matkovic, M. Miravitllesevidence emerging. For example M. catarrhalis, previously
known as Neisseria catarrhalis or Branhamella catarrhalis,
was first considered as a non-PPM35 but is now deemed as
a PPM.16,23,28,34 The opposite situation might occur in the
near future with H. haemolyticus and H. parainfluenzae,
since recent findings have suggested their pathogenic
potential to be much lower in comparison to other
PPMs4,18,36,37 and some authors have already started to
categorise them as non-PPMs.33,36 Among PPMs, NTHi, S.
pneumoniae, M. catarrhalis and H. parainfluenzae are the
most frequently recovered in stable COPD
patients,2,18,25,27,34,38e40 while Pseudomonas spp. predom-
inantly appear in more advanced disease.17,26 However, it is
not unusual for more than one pathogen to simultaneously
be isolated in the same patient.2,17,25,40
It is commonly believed that the lower respiratory tract
of healthy non-smoking individuals is sterile, but some
investigators have shown that lower airways of healthy
subjects can also be colonised,2,16,26,28 although the colo-
nisation rate is relatively low (4e40%) and caused mainly by
non-PPMs (Tables 1 and 2). The exception is the study
by Weinreich et al.26 in which even 90% of healthy subjects
(current smoking status unknown) had positive cultures
of BL samples, although PPMs were isolated in only 10%
(Table 2).
The rates of positive cultures in stable COPD vary
depending on the sampling technique and the cut-off points
employed. In the studies using sputum samples up to 100%
of cultures were positive for any bacteria, while 38e74%
were positive for PPMs (Table 3).14,17,18,25,39,40 With PSB
samples, the colonisation rate was somewhat lower, asTable 1 Percentages of positive bacterial cultures using protect
with COPD and bronchiectasis.
Source Patients, N FEV1,
% pred
Spec
cut-o
for p
cultu
CFU/
Rosell et al.2 Healthy, 70 (49% smokers) 92 PSB/
Stable COPD, 181 56
Exacerbated COPD, 86 37
Monso et al.27 Stable COPD, 40 51 PSB/
Exacerbated COPD, 29 44
Cabello et al.28 Healthy, 16 (12% smokers) 92 PSB/
Stable COPD, 18 77
Stable bronchiectasis, 17 73
Ruse et al.29 Stable CB, 42 (45% with COPD) 79 PSB/
Monso et al.30 Stable CB, 41 75 PSB/
Zalacain et al.31 Controls, 20 (10% smokers) 88 PSB/
Stable COPD, 88 56
Angrill et al.32 Stable bronchiectasis, 75
(49% with COPD)
75 PSB/
Soler et al.33 Exacerbated COPD, 40 37 PSB/
COPD: chronic obstructive pulmonary disease; CB: chronic bronchit
microorganism; FEV1: forced expiratory volume in one second; CFU: co
Moraxella catarrhalis; Sp: Streptococcus pneumoniae; Pa: Pseudomo
Staphylococcus aureus.expected, ranging from 22 to 83%, with PPMs isolated in
25e31% (Table 1).2,19,27e31 Similarly, BAL and BL cultures
were positive in 13e89% of cases, with PPMs isolated in
33e43% (Table 2).16,19,26,28
In most of the studies investigating distal airway colo-
nisation in COPD, patients with previously proven bronchi-
ectasis were excluded from the analysis. After the
introduction of high-resolution computed tomography
(HRCT) in the routine clinical practice, it has become clear
that bronchiectasis of different degrees and extent is
a common feature in COPD patients.41,42 Therefore, it is
expected that the prevalence rate of bronchial colonisation
in COPD could be even higher than suggested by the
previously mentioned studies. In agreement with this
presumption, the colonisation rate with PPMs was of up to
63% in the two studies in which bronchoscopic sampling was
preformed in stable patients with bronchiectasis and COPD
(Tables 1 and 2).26,32 Furthermore, in the study on stable
COPD by Patel et al.,41 after excluding patients with
previously diagnosed or clinically evident bronchiectasis,
up to 50% of the study population fulfilled radiological
criteria for bronchiectasis on HRCT and a positive correla-
tion was found between lower lobe bronchiectasis, distal
airway colonisation and bronchial inflammation. In a more
recent study by Martinez-Garcia et al.42 the prevalence of
subclinical bronchiectasis in stable COPD was even higher
(58%), and was significantly associated with a higher rate of
bronchial colonisation and increased systemic inflammation
measured by fibrinogen plasma levels.
The sensitivity of the novel, nonculture-based tech-
niques to detect the presence of microorganisms is evened specimen brush (PSB) samples in healthy subjects, patients
imen/
ff value
ositive
re,
ml
Culture
positive
for any
bacteria,
N (%)
Culture
positive
for PPM,
N (%)
Culture
positive
for
nonPPM
N (%)
Most
frequently
isolated
PPMs
102 e 3 (4%) e Hi
53 (29%) Hi, Sp, Mc
46 (54%) Hi, Pa, Sp, Mc, En
103 e 10 (25%) e Hi, Sp
15 (52%) Hi, Sp, Pa, Mc
102 2 (12%) e e Sa
15 (83%) Hi, Sp, Sa
14 (82%) Hi, Pa, Sa
>103 10 (24%) e e Sp, Hi
103 9 (22%) e e Hi, Sp
103 0 (0%) e e e
36 (41%) 27 (31%) Hi, Sp, Mc
102 e 46 (61%) 22 (29%) Hi, Pa, Sp, Mc
102 27 (68%) 18 (45%) 10 (25%) Hi, Sp, Mc, Pa
is; PSB: protected specimen brush; PPM: potentially pathogenic
lony forming units; Hi: nontypeable Haemophilus influenzae; Mc:
nas aeruginosa; En: members of Enterobacteriaceae family; Sa:
Table 2 Percentages of positive bacterial cultures using bronchoalveolar or bronchial lavage samples in healthy subjects,
patients with COPD and bronchiectasis.
Source Patients, N FEV1,
% pred
Specimen/
cut-off value
for positive
culture,
CFU/ml
Culture
positive
for any
bacteria,
N (%)
Culture
positive
for PPM,
N (%)
Culture
positive
for nonPPM
N (%)
Most
frequently
isolated
PPMs
Sethi et al.16 Healthy, 15
(non-smokers)
99 BAL/102 e 1 (7%) 6 (40%) Hp
Healthy, 20
(ex-smokers)
90 0 (0%) 4 (20%) e
Stable COPD, 26 60 9 (35%) 6 (23%) Hi, Hp
Soler et al.19 Controls, 12
(100% smokers)
94 BAL/103
þ PSB/102
e 5 (42%) 7 (58%) Sp, Sa, Hi, Mc
Stable COPD, 52 28e65 17 (33%) 28 (54%) Sp, Sa, Hi, Mc
Weinreich et al.26 Healthya, 48 3.0 L BL/102 43 (90%) 5 (10%) e Hi, Sp
Stable COPD, 53 1.2 L 47 (89) 23 (43%) Hi, Sp
Stable
bronchiectasis, 32
1.8 L 31 (97%) 20 (63%) Hi, Sp, En, Pa
Cabello et al.28 Healthy
(12% smokers), 15
92 BAL/103 2 (13%) e e e
Stable COPD, 16 77 2 (13%) Sp
Bronchiectasis, 13 73 10 (77%) Hi, Pa
Angrill et al.32 Stable bronchiectasis,
59 (49% with COPD)
75 BAL/103 e 33 (56%) 19 (32%) Hi, Pa, Sp
COPD: chronic obstructive pulmonary disease; CB: chronic bronchitis; BQ: bronchiectasis; PSB: protected specimen brush; BAL: bron-
choalveolar lavage; BL: bronchial lavage; PPM: potentially pathogenic microorganism; FEV1: forced expiratory volume in one second;
CFU: colony forming units; Hi: nontypeable Haemophilus influenzae; Hp: Haemophilus parainfluenzae; Mc: Moraxella catarrhalis; Sp:
Streptococcus pneumoniae; Pa: Pseudomonas aeruginosa; En: members of Enterobacteriaceae family; Sa: Staphylococcus aureus.
a Current smoking status not provided.
Infective phenotype in COPD 13greater. It has recently been demonstrated that with the
use of PCR techniques, microbial nucleic acid can be
extracted from a certain proportion of culture negative
respiratory specimens.21,22 Assuming that nucleic acid
represents viable bacteria, this would indicate even higher
rates of colonisation than culture findings have suggested.
Additionally, some microorganisms are able to invade and
survive within airway epithelial cells and macrophages.43,44
With the use of in situ hybridisation and immunofluores-
cence microscopy for the detection of intracellular NTHi in
bronchial biopsies, this microorganism was found in 33% and
87% of stable and severely exacerbated chronic bronchitis
patients, respectively, but not in healthy adults.24
Themost frequently identified risk factors for colonisation
with PPMs are current or previous smoking,25,30,31 impaired
lung function defined by a reduction in FEV1 and/or forced
vital capacity (FVC),2,30,31 comorbid conditions,25 increased
rate of previous exacerbations25,39 and the presence of
bronchiectasis.26,42Purulentsputumandanincreaseddegree
of dyspnoea are also recognised as clinical indicators of
positive sputum cultures for PPMs in stable COPD.25Microbial colonisation or chronic bronchial
infection?
The hostepathogen interaction is complex but crucial for
the establishment and proliferation of microorganisms inthe lower airways. This interaction is best described for
NTHi and involves adherence to mucous membranes and
extracellular matrix, damage to epithelial cells, ciliotoxic
activity, an increase in mucin production, as well as
complex mechanisms of evading host immune defences
such as invasion into the epithelial cells, production of IgA
proteases and antigenic heterogeneity.44,45 Some host
factors such as reduced mucociliary clearance, mucus
hypersecretion and bronchiectasis are also involved,26
although it is not always clear whether some these
features are really risk factors for acquiring bacteria or
their consequence. Recent findings have stressed the role
of innate immunity impairment in COPD, which among
others, may manifest as defective phagocytosis and hypo-
responsiveness of alveolar macrophages to bacterial anti-
gens, leading to reduced clearance of bacterial pathogens
and subsequent predisposition to colonisation and
infection.46,47
COPD is characterised by different degrees of chronic
inflammation affecting the large and small airways as well
as the lung parenchyma and pulmonary vasculature.29,48,49
Considering COPD as an inflammatory disorder, several
studies have attempted to clarify the impact of bacterial
colonisation in mediating this inflammatory process,
beyond the effect of cigarette smoking. Bacteria release
molecules with potent proinflammatory effects such as
endotoxins (e.g. lipooligosaccharide of NTHi), outer
membrane lipoproteins (e.g. outer membrane protein
Table 3 Percentages of positive sputum cultures in stable COPD and most frequently isolated pathogens.
Source Patients, N FEV1,
% pred.
Specimen,
N/cut-off
value for
positive
culture,
CFU/ml
Culture
positive
for any
bacteria,
N (%)
Culture
positive
for PPM,
N (%)
Most
frequently
isolated
PPMs
Papi et al.1 Stable, convalescent
COPD (8e10 weeks
after an exacerbation), 64
50 I sputum,
64/106
e 24 (38%) Hi, Sp, Mc, Sa
Wilkinson et al.14 Stable COPD, 30 35 S or I sputum,
30/>105
30 (100%) At baseline:
16 (53%)
After 1 year:
17 (57%)
Hi, Mc, Hp
Hill et al.17 Stable CB, 160: S sputum,
336/105
e 247 (74%) Hi, Hp, Mc, Pa
- COPD, 55 28
- COPD with A1AT
def, 62
21
- bronchiectasis, 43 62
Marin et al.18 Stable COPD, 40 58 I sputum,
79/102
e At baseline:
58 (73%)
After 9 months:
56 (71%)
Hi, Pa, En, Hp
Miravitlles et al.25 Stable COPD, 119 46 S or I sputum,
119/102
e 58 (49%) Hi, Hp, Pa
Patel et al.39 Stable COPD, 29 39 I sputum, 29/
cut-off not
provided
e 15 (52%) Hi, Sp
Banerjee et al.40 Stable COPD, 67 w40 I sputum, 67/
cut-off not
provided
67 (100%) 27 (40%) Hi, Mc, Sp
COPD: chronic obstructive pulmonary disease; CB: chronic bronchitis; A1AT def: alpha 1-antitrypsin deficiency; PPM: potentially
pathogenic microorganism; FEV1: forced expiratory volume in one second; CFU: colony forming units; S: spontaneously expectorated; I:
induced; Hi: nontypeable Haemophilus influenzae; Hp: Haemophilus parainfluenzae; Mc: Moraxella catarrhalis; Sp: Streptococcus
pneumoniae; Pa: Pseudomonas aeruginosa; En: members of Enterobacteriaceae family; Sa: Staphylococcus aureus.
14 Z. Matkovic, M. Miravitlles[OMP] P2 and OMP P6 of NTHi), peptydoglican fragments,
lipoteichoic acid, toxins (e.g. pneumolysin from S. pneu-
moniae), and others.20,50e52 In response to these bacterial
molecules, airway epithelial cells and macrophages
produce a variety of different inflammatory mediators (e.g.
interleukin [IL]-6, IL-8, IL-10, tumour necrosis factor [TNF]-
a, macrophage chemotactic protein [MCP]-1, macrophage
inflammatory protein [MIP]-1a), which further lead to
recruitment and activation of neutrophils, macrophages
and other inflammatory cells.51e54 The neutrophils, which
prevail in the bronchial secretions of COPD patients and
healthy smokers,19 are recruited from the circulation and
activated in response to chemoattractants, particularly IL-8
and leukotriene B4 (LTB4) via adhesion molecules, such as
E-selectin and intercellular adhesion molecule (ICAM)-1,
expressed on the vascular endothelium. The activated
neutrophils degranulate releasing myeloperoxidase and
different types of proteinases (elastase, cathepsin G,
proteinase 3, matrix metalloproteinase), which together
participate in various aspects of tissue damage.38
Colonised COPD patients have higher concentrations of
inflammatory cytokines, neutrophils and their products inrespiratory secretions in comparison with non-colonised
patients with a similar degree of airflow obstruction, which
would indicate a higher level of airway inflammation
induced by bacteria.15,16,40 Different bacterial species and
even different strains of the same species differ in viru-
lence and inflammatory potential.4,17,55 In the study by Hill
et al.,17 P. aeruginosa was recognised as the most potent
inducer of inflammation followed by NTHi, whereas M.
catarrhalis provoked a significantly milder reaction. Addi-
tionally, Sethi et al.4 demonstrated the significant inflam-
matory potential of NTHi and M. catarrhalis, while H.
parainfluenzae-associated exacerbations had an inflam-
matory profile similar to PPM-negative exacerbations.
Furthermore, there is an interspecies diversity in the
duration of colonisation, e.g. M. catarrhalis is usually
cleared from the respiratory tract efficiently, even without
antibiotics, within a period of only one month,23 while the
carriage of NTHi and P. aeruginosa, particularly the mucoid
strains, may last much longer.18,21,22
Bacterial colonisation is a dynamic process with changes
in pathogens, their strains and loads occurring over
time.3,14,18,21,23 It has been suggested that a change in
Infective phenotype in COPD 15bacterial strain and/or a rise in bacterial load can increase
the degree of airway and systemic inflammation and trigger
the onset of an exacerbation,3,10,12,17,56,57 which will be
discussed in more detail later. Most adults who acquire
bacteria in their respiratory tract develop an immune
response, as has been demonstrated in the study by Murphy
et al.23 in which 72% of episodes of acquisition of M.
catarrhalis were followed by a systemic (serum IgG) and/or
mucosal (sputum IgA) antibody response to the homologous
strain. It is of clinical importance that colonised patients
have worse health status,40 increased exacerbation
frequency as well as more symptoms during exacerba-
tions.39 Bacteria may also contribute to an accelerated
decline in lung function and, consequently, to progression
of COPD. This is supported by the study of Wilkinson
et al.,14 in which a decline in FEV1 was related to a change
in the colonising bacterial type and a rise in airway
bacterial load. This observation was confirmed by a more
recent study in patients with moderate COPD, in which
neutrophilic airway inflammation, mainly found in patients
colonised by PPMs, was associated with more than a two-
fold increased risk of FEV1 decline over the median
decline during follow-up.18 Bacteria may accelerate FEV1
decline by both, directly increasing basal airway inflam-
mation in the stable state, as well as by indirectly inducing
more frequent and severe exacerbations.14,18,39
In view of the above, it is clear that the isolation of
PPMs from respiratory samples does not fulfil the definition
of “colonisation”, because it is associated with an inflam-
matory response and significant damage to the target
organ. This is why it has recently been suggested that the
term chronic bronchial infection would be more appro-
priate when addressing the presence of significant
concentrations of PPMs in the lower airways of stable COPD
patients.13,58 Chronic bronchial infection in COPD can be
defined as the presence of PPMs in respiratory secretions
that cause an inflammatory reaction manifested by the
chronic production of coloured/purulent sputum. This
syndrome can be accompanied by recurrent infective
exacerbations and systemic manifestations in the form of
malaise, febricula, asthenia or weight loss, similar to what
has been described in patients with bronchiectasis.59 In
fact, most of these patients have significant bronchiectasis
when studied by HRCT scan. In the study by Martinez-
Garcı´a et al.42 the isolation of a PPM in sputum in a patient
with stable COPD, together with a FEV1 <50% predicted and
the history of at least one hospital admission for an exac-
erbation the previous year were associated with a 99%
probability of having bronchiectasis on CT scan.
Conversely, the term colonisation should only be used to
describe the isolation of non-PPMs from the distal respira-
tory tract, either in healthy subjects or in patients with
a chronic airway disease.
Besides common bacteria, respiratory viruses and atyp-
ical bacteria in the form of chronic infection may also have
an impact on the course of COPD.8,48,60 Seemungal et al.8
analysed nasal aspirates and blood samples of stable
COPD patients by PCR and detected low-grade viral infec-
tion with respiratory syncytial virus (RSV) in 24% of
patients, as well as infection with viruses other than RSV
(dominantly rhinoviruses and coronaviruses) in 16% of
patients. Patients in whom virus was detected were morelikely to have increased exacerbation frequency as well as
higher concentrations of serum IL-6 and plasma fibrinogen
(potential predisposition to thrombotic events) when
stable.8 Furthermore, examining lung tissue of smokers
with different degrees of emphysema, Retamales et al.49
determined a 5- to 40-fold increase in the number of
alveolar epithelial cells expressing adenoviral E1A protein
in mild and severe emphysema, respectively, and suggested
the impact of latent adenoviral infection on the amplifi-
cation of cigarette smoke-induced lung inflammation which
is present in severe emphysema. In addition to promoting
an inflammatory process, lower respiratory viral or atypical
bacterial infection may enhance the susceptibility of the
airways to other pathogens.60,61 One example is chronic
Chlamydophila pneumoniae infection in COPD patients,
which has been associated with a higher rate of airway
colonisation with common bacteria, frequent exacerba-
tions and more severe functional impairment.60From chronic bronchial infection to
exacerbation of COPD
Exacerbations are relatively frequent events in the course
of COPD, especially in moderate-to-severe disease, with
a significant impact on health status, quality of life,62,63
disease progression,64 mortality,65,66 health-care uti-
lisation and costs.67,68 Before discussing the role of micro-
organisms in the exacerbation of COPD (ECOPD), it should
be mentioned that there is still no standardised definition
of ECOPD.69,70 The reason for this probably lies in the
complex pathophysiology and the different aetiologic
factors involved, as well as in the variety of clinical mani-
festations presented by these patients. The American
Thoracic Society/European Respiratory Society (ATS/ERS)
Task Force on COPD71 defines ECOPD as an increase in
respiratory symptoms over baseline that usually requires
a change in therapy. Nonetheless, the most widely used
clinical criteria for ECOPD are increased dyspnoea, sputum
volume and sputum purulence as defined by Anthonisen
et al.72 based on the probability of response to antibiotic
therapy.
Despite all the limitations in defining ECOPD, investiga-
tions preformed in recent years have sought to establish the
underlying pathophysiological process of these events. In
comparison to the stable state, there is an acute increase in
the level of airway inflammation during periods of exacer-
bations, assessed by the rise in sputum inflammatory cells
(neutrophils, eosinophils and lymphocytes) and different
inflammatory mediators including IL-6, IL-8, LTB4, TNFa,
neutrophil proteases, myeloperoxidase, eosinophil cationic
protein (ECP) and RANTES (Regulated upon Activation,
Normal T-cell Expressed and Secreted).1,4,50,54,57,58,73e75
Intensified inflammation may induce airway mucosal
oedema, bronchospasm and mucus hypersecretion, which
further lead to increased respiratory symptoms.12 The
association between neutrophilic inflammation, sputum
purulence and bacterial exacerbations is well established
and provides a rationale for using sputum purulence as
a clinical indicator of bacterial infection and the need for
antibiotic therapy.4,10,33,74,76,77 Additionally, sputum neu-
trophilia positively correlates with the severity of an
16 Z. Matkovic, M. Miravitllesexacerbation assessed by the impairment in lung function
and the level of hypoxia.1 Inflammation in ECOPD is not only
limited to the lower airways. There is also a certain degree
of upper airway and systemic inflammation, which is
proportional to the lower airway inflammation and is higher
in bacterial exacerbations.58,73,74,76 Furthermore, the clin-
ical severity of exacerbations is significantly correlated
with the level of local and systemic inflammation.57
Published data suggest that up to 70% of exacerbations
are caused by respiratory infections including aerobic
bacteria (40e60%), respiratory viruses (about 30%) and
atypical bacteria (5e10%).11,78 Some authors have demon-
strated polymicrobial aetiology in as much as 33% of exac-
erbations, being particularly important in the most severe
cases.1,79,80 Environmental factors including low tempera-
ture and air pollution (exposure to higher levels of black
smoke particulate matter, sulphur dioxide, nitrogen dioxide
and ozone) are considered as the cause of approximately
10% of ECOPD, depending on the season and geographical
setting.78,81e83 Furthermore, non-compliance with therapy
and/or abrupt withdrawal of therapy are provocation
factors in some exacerbations.84 Nonetheless, in a certain
proportion of ECOPD the aetiology remains unknown.
Considering bacterial exacerbations, NTHi, S. pneumo-
niae and M. catarrhalis are the most frequently isolated
PPMs from respiratory secretions during exacerbations,
similar to what occurs in the stable state.1,2,27,85 Other
Gram-negative bacteria such as P. aeruginosa, Steno-
trophomonas maltophilia and members of the Enter-
obacteriaceae family are more often present in patients
with a greater degree of functional impairment, recent
antibiotic or systemic steroid therapy, and in those with
severe exacerbations.85e87
Interestingly, PPMs are isolated more frequently and in
higher loads during exacerbations compared to the stable
state. They can be found in about 50% of exacerbated
patients when using PSB samples (Table 1), usually with
>107 CFU/ml in sputum cultures and >103 CFU/ml in PSB
cultures.1,2,10,27,79 As mentioned previously, when search-
ing for the presence of NTHi intracellularly in the bronchial
mucosa in exacerbated chronic bronchitis, NTHI was
detected more frequently in comparison with the stable
state.24 All these findings and the fact that the severity of
bronchial inflammation is directly correlated with bacterial
load17 led to the development of the “fall and rise” or
quantitative hypothesis of bacterial ECOPD.10 Based on this
hypothesis, symptoms of exacerbation appear when the
inflammatory reaction caused by the increasing bacterial
load in the airways exceeds a certain threshold, which is
determined by a combination of bacterial and host
factors.10 On the other hand, recent findings based on
molecular typing of bacterial isolates have suggested that
the acquisition of new strains of bacteria or antigenic
change in pre-existing strains are crucial in the pathogen-
esis of bacterial exacerbations, and that the change in the
bacterial load with subsequent enhancement of inflamma-
tion are just secondary phenomena.3,12,22,34,57 Following
a cohort of ambulatory COPD patients during more than
four years, Sethi et al.3 demonstrated that the acquisition
of a new strain of NTHi, S. pneumoniae and M. catarrhalis
was associated with more than a two-fold higher risk for an
exacerbation. In a more recent study of a similar design butwith a longer follow-up, Murphy et al.22 have shown that
the same association between change in a strain and
occurrence of exacerbations also exists for P. aeruginosa. It
is suggested that after a new strain is acquired due to the
absence of an effective host immune response, bacteria
may intensively proliferate in the airways resulting in
a higher bacterial load, more severe local and systemic
inflammation and the development of symptoms of exac-
erbation.12,57 The immune response to the infecting strain,
which develops after an ECOPD, is strain-specific and not
protective against acquisition of new strains,5,23,88,89which
may explain recurrent exacerbations even by the same
species.56 Moreover, this specific immune response provides
indirect evidence that the particular microorganism was
actually the cause of the exacerbation.5,23,88,89 However,
a change in strain may not be the only mechanism of
exacerbations. In the previously mentioned studies,3,22 only
33% and 43%, respectively, of the visits involving isolation of
a new bacterial strain were associated with the onset of an
exacerbation. Additionally, in both studies a certain
proportion of exacerbations were diagnosed at visits in
which the isolated bacteria did not belong to a new strain,
and also some exacerbations occurred at visits without
isolation of any bacterial pathogen. It seems that the
increase in airway inflammation and clinical manifestations
of exacerbation are the result of a complex hostepathogen
interaction in which a change in a bacterial strain plays
a central role, but other factors may influence as well, e.g.
host defences, virulence capacity of different strains or
bacterial species, the presence of microorganisms other
than bacteria and non-microbial provocation factors,
among others.3,12,13,36,56,90Role of viruses and atypical bacteria in
exacerbations of COPD
The role of viruses and atypical bacteria in ECOPD has
recently received increasing attention thanks to novel
diagnostic techniques such as PCR and reverse transcription
PCR (RT-PCR), which have a higher sensitivity in detecting
these pathogens compared with previously established
methods (cell cultures, serology). In a systematic review on
the prevalence of viral infection in ECOPD7 including eight
studies using PCR and/or RT-PCR in sputum and nasal lavage
fluid samples, the weighted mean prevalence of respiratory
viral infection was 34%, being as high as 56% in one of these
studies.91 Picornavirus (especially rhinovirus) was most
commonly detected, followed by influenza (prevalence
depended on the vaccination status of the study pop-
ulation) and respiratory syncytial virus. Coronavirus, para-
influenza, adenovirus and human metapneumovirus were
detected in significantly smaller percentages.7,8 Consid-
ering the clinical presentation, viral exacerbations have
been associated with a higher total symptom count at
presentation, a higher frequency of additional symptoms
(cold, sore throat, increased dyspnoea, fever), slower
recovery and frequent previous exacerbations.8
Direct evidence of the causal relationship between viral
infections and ECOPD has recently been obtained in the
study by Mallia et al.9 who demonstrated that experimental
rhinovirus infection in subjects with COPD induces clinical
Infective phenotype in COPD 17and inflammatory changes similar to those seen in naturally
occurring exacerbations. After infection with rhinovirus,
COPD patients developed more severe and prolonged
respiratory symptoms, greater lung function impairment
and increased airway inflammation in comparison with
healthy controls. These authors suggested that experi-
mental rhinovirus infection may be used in the future as
a human model of ECOPD.9
Atypical bacteria such as C. pneumoniae, Mycoplasma
pneumoniae and Legionella spp. are intracellular patho-
gens that share some characteristics of viruses.78 Their
contribution in the emergence of exacerbations is not
completely clear because the data on their prevalence
significantly differ depending on the diagnostic methods
and study populations involved.6,92e95 It is commonly
accepted that atypical bacteria cause 5e10% of ECOPD,11,78
either as independent pathogens or, more frequently, as
co-pathogens.80,93,94 However, in several serologic studies,
much higher proportions of exacerbated patients had
evidence of a recent infection with C. pneumoniae, M.
pneumoniae or Legionella spp. e up to 34%, 14% and 17%,
respectively.6,92e94
Polymicrobial aetiology is frequently found in the most
severe ECOPD and manifests either as simultaneous co-
infection, secondary bacterial after a viral infection or vice
versa.5,79,80 One of the proposed mechanisms of interaction
between viruses and bacteria includes changes in the
receptor molecules on the respiratory epithelial cells
induced by one microorganism leading to increased
susceptibility to the other microorganism.13,61 There is
evidence that patients with polymicrobial exacerbations
have more severe deterioration in lung function, a higher
symptom count and longer hospitalisation.1,79Is COPD a chronic infective disease?
Although smoking cessation is effective in slowing the
accelerated decline in lung function, it has been observed
that the inflammatory process in the lungs of patients with
COPD continues after smoking cessation, and in some
aspects may even increase, contrary to the case in healthy
ex-smokers whose airway inflammation usually
decreases.96,97 Furthermore, inflammation in COPD patients
is not limited to their lungs; namely, they have persistent
systemic inflammation as well.98 Some of the suggested
promoters of this on-going inflammation in ex-smoking COPD
patients are microorganisms, autoimmunity, inflammation as
part of a repair process, recovery of the proinflammatory
capacity of epithelial cells after smoking cessation or
disappearance of anti-inflammatory factors such as carbon
monoxide from cigarette smoke.96 However, after review of
the evidence, microorganisms emerge as the most likely
“candidates” to perpetuate bronchial inflammation. In
favour of this hypothesis, Moller et al.99 detected H. influ-
enzae more frequently in tissue sections of lungs from
patients with COPD and cystic fibrosis than from others when
analysing lung explants from transplant recipients with
different end-stage pulmonary diseases. Their results indi-
cate a generalised distribution of H. influenzae in the lungs
of these patients, with the presence of bacteria in the
epithelium and submucosa of the bronchi and bronchioles,parenchymal lung tissue (alveolar epithelium, interstitium,
alveoli), as well as in the visceral pleura.99 Other in vitro and
in vivo studies have confirmed the ability of bacteria to
invade lung tissue and persist therein.24,43 Apart from the
frequent intraluminal localisation of bacteria in the airways
of COPD patients, it has been suggested that such “tissue
reservoir” protects these patients from the circulating
antibiotics and effective host immune defences may serve as
an endogenous source for recurrent infections as well as
a chronic inflammatory stimulus.43,52 The hypothesis of
chronic microbial stimulation is supported by the histological
changes observed in the lungs of COPD patients. Namely,
besides tissue remodelling, progression of the disease leads
to increased infiltration of the small airways by the
lymphocytes and their organisation into lymphoid follicles,
probably as an adaptive immune response to persistent
microbial stimulation.100
Evidence suggests that, together with smoking, microor-
ganisms play a significant role in the development and
progression of COPD. The sequence of events in the patho-
genesis of COPD with microbial involvement is summarised in
Fig. 1. The most important difference with other chronic
infective disease is that COPD does not involve only one
causative pathogen but rather there is a change in the
pathogens, their strains and loads occurring over time.
Whether this influence of infection exists for all COPD
patients or only for those with an “infective phenotype” still
needs to be established since most of the previous longitu-
dinal studies investigating this issue have only included COPD
patients with chronic bronchitis. In fact, even exacerbations
themselves may have different phenotypes. Bacterial exac-
erbations present with a particular inflammatory profile that
is different from the viral, the so-called eosinophilic-
predominant and the pauciinflammatory.101 Interestingly,
the bacterial exacerbation phenotype can be identified from
the stable state in patients with an “infective phenotype”
and these patients will develop the same type (or pheno-
type) of bacterial exacerbation in successive episodes.101
This infective phenotype of COPD could be described as
patients with chronic production of coloured sputum during
a stable state, recurrent bacterial exacerbations and
frequently associated bronchiectasis. In other words, the
infective phenotype in COPD refers to patients with the
syndrome of chronic bronchial infection.
However, many aspects of the relationship between
infection (acute and chronic) and COPD require further
research, e.g. the significance of simultaneous isolation of
multiple bacterial strains, possible cooperation of PPMs and
non-PPMs in disease progression and the development of
antibiotic resistance, mechanisms of interactions of
different pathogens in polymicrobial infections as well as
the relation between microbial and environmental factors
in the pathogenesis of exacerbations. The use of novel,
molecular, cellular and immunologic techniques is crucial
for progress in this research. In addition, efforts should be
made to seek new, reliable, non-invasive methods for
detection of lower airway infection/inflammation in order
to avoid limitations of sputum cultures and the inconve-
nience of bronchoscopic sampling. Further evidence on the
impact of bacteria in COPD can be expected from the
results of the currently ongoing clinical trials on antibiotics in
stable COPD.102,103 Finally, the relevance of the described
Figure 1 The impact of microbial infection on the pathogenesis of COPD, both in the stable state and in exacerbations. Since the
current evidence for the role of atypical bacteria is incomplete, they are presented with a dashed line. COPD: chronic obstructive
pulmonary disease; PPM: potentially pathogenic microorganism.
18 Z. Matkovic, M. Miravitllesmicrobiota on lung health must be established. Molecular
culture-independent techniques have identified bacteria
previously not amenable to culture. Analysis of the highly
conserved 16S rRNA gene has been used to assign phylogeny
and allows a picture of the completemicrobial community in
an environment (the bronchial tree) to be constructed,
offering a more comprehensive analysis than classical
culture-based techniques.104 The number of studies exam-
ining the lower airways microbiome is limited and there is
some overlap between bacteria seen in COPD and healthy
individuals105; however, a recent study has reported a signifi-
cantly different bacterial community (microbiome) in
patients with very severe COPD compared with nonsmokers,
smokers and patients with cystic fibrosis.106 Further studies
are clearly needed to understand the role of these micro-
biomes in healthy individuals and patients with COPD.Acknowledgements
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